Observational Study
Copyright ©The Author(s) 2022.
World J Diabetes. Dec 15, 2022; 13(12): 1154-1167
Published online Dec 15, 2022. doi: 10.4239/wjd.v13.i12.1154
Table 2 Clinical and demographic characteristics of patients type 2 diabetes and coronavirus disease 2019 infection, with and without albuminuria

Diabetic patients without baseline albuminuria, n = 45
Diabetic patients with baseline albuminuria, n = 20
P value
Age (yr), mean (SD)58.7 (9.2)62.2 (9.0)0.161
Median (IQR)60.0 (50.5-65.0)63.0 (56.5-68.8)
Sex, female, n (%)21 (46.7)11 (55.0)0.602
Population group, n (%)0.772
Jews13 (28.9)7 (35.0)
Arabs 32 (71.1)13 (65.0)
BMI (kg/m2), mean (SD)31.6 (4.5)33.2 (4.6)0.191
Median (IQR)30.9 (28.6-33.7)32.3 (29.7-35.9)
Diabetes duration (yr), median (IQR)10.0 (5.5-14.0)11.0 (5.3-17.0)0.251
eGFR (mL/min/1.73 m2 body surface area) at baseline, median (IQR)90.5 (77.8-99.5)95.3 (69.6-101.1)0.903
HbA1c (%), median (IQR)7.2 (6.6-8.4)8.9 (7.3-10.4)0.023
Metformin, n (%)41 (91.1)15 (75)0.124
DPP-4 inhibitors, n (%)15 (33.3)3 (15)0.152
Sulfonylurea, n (%)5 (11.1)2 (10)1.004
SGLT2 inhibitors, n (%)15 (33.3)3 (15)0.152
GLP-1 agonists, n (%)8 (17.8)4 (20)1.004
Basal insulin, n (%)8 (17.8)10 (50)0.0152
Prandial insulin, n (%)2 (4.4)4 (20)0.0674
Current smoking, n (%)2 (4.4)2 (10)0.584
Retinopathy, n (%)4 (12.9)3 (20)0.674
NLRmax, median (IQR)6.2 (2.5-9.4)6.7 (2.6-18.0)0.483
CRP (mg/L) at admission, median (IQR)90.4 (10.9-153.6)43.9 (12.5-106.8)0.333
CRPmax (mg/L) at hospitalization, median (IQR)92.8 (11.4-171.3)61.0 (12.5-157.3)0.603
eGFR (mL/min/1.73 m2 body surface area) at hospitalization, median (IQR)90.3 (77.0-98.4)94.3 (67.8-101)0.763
Albumin, median (IQR)3.6 (3.3-4.0)3.6 (3.1-3.9)0.251